Literature DB >> 23209290

The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.

Ishrut Hussain1, Julien Fabrègue, Laurence Anderes, Solenne Ousson, Frédéric Borlat, Valérie Eligert, Sébastien Berger, Mitko Dimitrov, Jean-René Alattia, Patrick C Fraering, Dirk Beher.   

Abstract

γ-Secretase is a large enzyme complex comprising presenilin, nicastrin, presenilin enhancer 2, and anterior pharynx-defective 1 that mediates the intramembrane proteolysis of a large number of proteins including amyloid precursor protein and Notch. Recently, a novel γ-secretase activating protein (GSAP) was identified that interacts with γ-secretase and the C-terminal fragment of amyloid precursor protein to selectively increase amyloid-β production. In this study we have further characterized the role of endogenous and exogenous GSAP in the regulation of γ-secretase activity and amyloid-β production in vitro. Knockdown of GSAP expression in N2a cells decreased amyloid-β levels. In contrast, overexpression of GSAP in HEK cells expressing amyloid precursor protein or in N2a cells had no overt effect on amyloid-β generation. Likewise, purified recombinant GSAP had no effect on amyloid-β generation in two distinct in vitro γ-secretase assays. In subsequent cellular studies with imatinib, a kinase inhibitor that reportedly prevents the interaction of GSAP with the C-terminal fragment of amyloid precursor protein, a concentration-dependent decrease in amyloid-β levels was observed. However, no interaction between GSAP and the C-terminal fragment of amyloid precursor protein was evident in co-immunoprecipitation studies. In addition, subchronic administration of imatinib to rats had no effect on brain amyloid-β levels. In summary, these findings suggest the roles of GSAP and imatinib in the regulation of γ-secretase activity and amyloid-β generation are uncertain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23209290      PMCID: PMC3554920          DOI: 10.1074/jbc.M112.370924

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Novel gamma-secretase inhibitors uncover a common nucleotide-binding site in JAK3, SIRT2, and PS1.

Authors:  Fang Wu; Claude Schweizer; Nikita Rudinskiy; David M Taylor; Aleksey Kazantsev; Ruth Luthi-Carter; Patrick C Fraering
Journal:  FASEB J       Date:  2010-03-17       Impact factor: 5.191

2.  Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin.

Authors:  Yvonne S Eisele; Matthias Baumann; Bert Klebl; Christina Nordhammer; Mathias Jucker; Ellen Kilger
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

3.  What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

Authors:  Nina F Schor
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 4.  Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

Authors:  Bruno P Imbimbo; Francesco Panza; Vincenza Frisardi; Vincenzo Solfrizzi; Grazia D'Onofrio; Giancarlo Logroscino; Davide Seripa; Alberto Pilotto
Journal:  Expert Opin Investig Drugs       Date:  2011-01-11       Impact factor: 6.206

5.  Mercury is a direct and potent γ-secretase inhibitor affecting Notch processing and development in Drosophila.

Authors:  Jean-René Alattia; Takayuki Kuraishi; Mitko Dimitrov; Isabelle Chang; Bruno Lemaitre; Patrick C Fraering
Journal:  FASEB J       Date:  2011-03-17       Impact factor: 5.191

6.  Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease.

Authors:  J Gregor Sutcliffe; Peter B Hedlund; Elizabeth A Thomas; Floyd E Bloom; Brian S Hilbush
Journal:  J Neurosci Res       Date:  2011-03-03       Impact factor: 4.164

7.  Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.

Authors:  Gen He; Wenjie Luo; Peng Li; Christine Remmers; William J Netzer; Joseph Hendrick; Karima Bettayeb; Marc Flajolet; Fred Gorelick; Lawrence P Wennogle; Paul Greengard
Journal:  Nature       Date:  2010-09-02       Impact factor: 49.962

Review 8.  Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain.

Authors:  Xuemin Xu
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 9.  gamma-Secretase modulators.

Authors:  Michael S Wolfe
Journal:  Curr Alzheimer Res       Date:  2007-12       Impact factor: 3.498

10.  TMP21 transmembrane domain regulates gamma-secretase cleavage.

Authors:  Raphaëlle Pardossi-Piquard; Christopher Böhm; Fusheng Chen; Soshi Kanemoto; Frédéric Checler; Gerold Schmitt-Ulms; Peter St George-Hyslop; Paul E Fraser
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

View more
  16 in total

Review 1.  Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls.

Authors:  Shashikala Bhute; Deepaneeta Sarmah; Aishika Datta; Pallavi Rane; Amit Shard; Avirag Goswami; Anupom Borah; Kiran Kalia; Kunjan R Dave; Pallab Bhattacharya
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-26

2.  The kinase ABL phosphorylates the microprocessor subunit DGCR8 to stimulate primary microRNA processing in response to DNA damage.

Authors:  Chi-Chiang Tu; Yan Zhong; Louis Nguyen; Aaron Tsai; Priya Sridevi; Woan-Yuh Tarn; Jean Y J Wang
Journal:  Sci Signal       Date:  2015-06-30       Impact factor: 8.192

3.  Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease.

Authors:  Sylvia E Perez; Muhammad Nadeem; Michael H Malek-Ahmadi; Bin He; Elliott J Mufson
Journal:  Neurodegener Dis       Date:  2017-07-26       Impact factor: 2.977

Review 4.  γ-Secretase inhibitors and modulators: Mechanistic insights into the function and regulation of γ-Secretase.

Authors:  Pengju Nie; Abhishek Vartak; Yue-Ming Li
Journal:  Semin Cell Dev Biol       Date:  2020-04-02       Impact factor: 7.727

Review 5.  Development and mechanism of γ-secretase modulators for Alzheimer's disease.

Authors:  Christina J Crump; Douglas S Johnson; Yue-Ming Li
Journal:  Biochemistry       Date:  2013-05-02       Impact factor: 3.162

6.  Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer's disease.

Authors:  Jin Chu; Jian-Guo Li; Yash B Joshi; Phillip F Giannopoulos; Nicholas E Hoffman; Muniswamy Madesh; Domenico Praticò
Journal:  Biol Psychiatry       Date:  2014-06-16       Impact factor: 13.382

7.  Chemotherapy and the Risk of Alzheimer's Disease in Colorectal Cancer Survivors: Evidence From the Medicare System.

Authors:  Igor Akushevich; Arseniy P Yashkin; Julia Kravchenko; Miklos D Kertai
Journal:  JCO Oncol Pract       Date:  2021-02-25

Review 8.  γ-Secretase in Alzheimer's disease.

Authors:  Ji-Yeun Hur
Journal:  Exp Mol Med       Date:  2022-04-08       Impact factor: 12.153

Review 9.  Complex regulation of γ-secretase: from obligatory to modulatory subunits.

Authors:  Natalya Gertsik; Danica Chiu; Yue-Ming Li
Journal:  Front Aging Neurosci       Date:  2015-01-06       Impact factor: 5.750

Review 10.  The γ-secretase complex: from structure to function.

Authors:  Xian Zhang; Yanfang Li; Huaxi Xu; Yun-Wu Zhang
Journal:  Front Cell Neurosci       Date:  2014-12-11       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.